Print this page
-
OCTANE: Adjuvant Liposomal Doxorubicin and Carboplatin for Early-Stage Triple-Negative Breast Cancer.
Protocol: 042304Principal Investigator:
- Mridula George (Rutgers University)
Applicable Disease Sites: Breast -
Statins for Reduction of Cardiac Toxicity in Patients Receiving HER2 Targeted Therapy.
Protocol: 042201Principal Investigator:
- Mridula George (Rutgers University)
Applicable Disease Sites: Breast -
Choices About Genetic Testing And Learning Your Risk with Smart Technology (CATALYST)
Protocol: 132307Principal Investigator:
- Anita Kinney PhD,RN (Rutgers University)
Applicable Disease Sites: Pancreas
Other Female Genital
Prostate
Colon
Ovary
Breast -
Cancer Analytics and South Asian Health Breast Cancer Survivor Study (CANSAH-BC).
Protocol: 132204Principal Investigator:
- Jaya Satagopan PhD (School of Public Health)
Applicable Disease Sites: Breast -
A Phase III Adjuvant Trial Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression plus Endocrine Therapy in Premenopausal Patients with pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score less than or equal to 25 (OFSET).
Protocol: 042313Principal Investigator:
- Mridula George (Rutgers University)
Applicable Disease Sites: Breast -
S2206, Phase III Trial of Neoadjuvant Durvalumab (NSC 778709) plus Chemotherapy versus Chemotherapy Alone for Adults with MammaPrint Ultrahigh (MP2) Hormone Receptor (HR) Positive / Human Epidermal Growth Factor Receptor (HER2) Negative Stage II-III Breast Cancer.
Protocol: 042315Principal Investigator:
- Mridula George (Rutgers University)
Applicable Disease Sites: Breast